Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > mj1981
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(99)
•••
Comment by Aarcoron Dec 03, 2021 12:23pm
100 Views
Post# 34195344

RE:RE:RE:RE:RE:mj1981

RE:RE:RE:RE:RE:mj1981Each of the last few years I'd asked you if you had bought any shares of Bioasis, and all I got back was dead air.  If you've acquired more shares, which I believe about as much as I believe in Santa, you've gathered them through private placements (with warrants) and/or corporate loans, just like Chrispi.

You have publicly supported management at every opportunity because you've either been on the payroll or want access to nifty private deals.  You've been wrong every single time you have argued about Bioasis - that is pretty hard to do.  Since you've resorted to ad hominem attacks, let me play too.  You're a shill and promoter and have a crew of simps that love you on this board.  Their allegiance to you and your grand prophecies has probably cost them more money than they wish to ever admit.  You like to throw around the word 'creep', but you're actually that guy.

Have a nice day.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities